Indian Journal of Nephrology · 2010 · 10 citations · 5 references
PharmacyPharmacokineticsPharmacologyDrug ClearanceRenal PharmacokineticsRenal PharmacotherapyDrug DispositionMetabolic ClearanceRenal ClearanceRenal Drug ClearanceRenal PharmacologyTransplant PharmacokineticsDrug Enterohepatic RecirculationMycophenolate PharmacokineticsMycophenolic Acid TherapyPharmacokinetics In Kidney DiseaseRecirculationRecovery Curve AnalysisRecovery TimeRifampicin Therapy
Renal transplant patients prescribed mycophenolate mofetil (MMF) may require treatment for tuberculosis with a regimen including the tuberculocidal drug rifampicin. MMF is an ester prodrug which is rapidly hydrolysed to the active compound, mycophenolic acid (MPA). Therapeutic drug monitoring of mycophenolate involves the measurement of MPA area under the curve (MPA-AUC(0-12)). Rifampicin is known to increase the metabolism and decrease enterohepatic recirculation of mycophenolic acid, (MPA). When MPA is monitored after the discontinuation of rifampicin, an important factor is the time required for the MPA area under the curve to return to the pre-rifampicin value. At present this is not known. This report describes one such renal allograft patient, on long term MMF and prescribed rifampicin by a local physician. As expected there was a clinically significant decrease in MPA-AUC(0-12) Three weeks after rifampicin was discontinued the MPA-AUC(0-12) was still only 65% of the pre-rifampicin value and only 55% of the steady state MPA-AUC(0-12) measured six months later.
5